Pilar Sepúlveda Sanchis

Title: Pilar Sepúlveda Sanchis: Innovator in Cardiotoxicity Prediction

Introduction

Pilar Sepúlveda Sanchis is a notable inventor based in Valencia, Spain. She has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracyclines chemotherapy. Her innovative approach utilizes a specific set of circulating microRNAs as biomarkers for this critical health issue.

Latest Patents

Pilar holds a patent titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention describes an in vitro method for assessing the risk of cardiotoxicity by determining the expression levels of a combination of ten circulating miRNAs. These include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also outlines a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout her career, Pilar has worked with esteemed institutions such as Maastricht University and Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana. Her research has focused on improving patient outcomes in cancer treatment through innovative methodologies.

Collaborations

Pilar has collaborated with notable professionals in her field, including Florian Caiment and David Hervàs Marin. These partnerships have contributed to the advancement of her research and the development of her patented methodologies.

Conclusion

Pilar Sepúlveda Sanchis is a pioneering inventor whose work in predicting cardiotoxicity risk has the potential to significantly impact cancer treatment protocols. Her innovative use of circulating miRNAs as biomarkers showcases her commitment to improving patient care and advancing medical research.